SPY
734.54
+0.21%
QQQ
657.87
+1.67%
BTC/USD
75,508.71
−0.60%
DIA
509.39
−0.95%
GLD
370.05
−1.45%
TLT
81.89
−0.05%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Jeremy Golden
About Jeremy Golden
Jeremy Golden is a U.S.-based writer who has contributed stories to newspapers, magazines and online publications across the Southeast. He has experience writing about finance, food, small businesses, athletics and other topics.
Articles by Jeremy Golden
Calibre Mining (OTC: CXBMF) Uses Artificial Intelligence To Push Gold Mining Operations Forward
Partner Content
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Partner Content
Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
Partner Content
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
Partner Content
New Study Shows Cardio Diagnostics' (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually
Partner Content
3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation
Partner Content
The Growing Market Demand For Waste Energy Solutions And How Sky Quarry Has Prepared Itself To Meet It
Partner Content
Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests
Partner Content
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Partner Content
Unlocking The Power Of Immunotherapy: Elicio Therapeutics' (NASDAQ: ELTX) Novel AMP Platform
Partner Content
Helping Build A Sustainable Future For Construction Materials – Sky Quarry's Innovative Approach To Recycling Shingles, Recovering Oil
Partner Content
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
Partner Content
Syra Health (NASDAQ: SYRA) Wins $650,000 Healthcare Quality Improvement Contract
Partner Content
Sky Quarry Is Paving The Way Toward A Potential Solution For The Multi-Billion Dollar Waste Asphalt Shingle Problem
Partner Content
Innoveren Scientific's (OTCMKTS: IVRN) 510(k) Submission Sparks A New Hope For Patients Living With Chronic Non-Healing Wounds
Partner Content
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC) Fights Cancer With Pelareorep, Which Has Received FDA Fast Track Designation For Breast And Pancreatic Cancer
Partner Content
Moving Fast: Candel's (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
Partner Content
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Partner Content
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Partner Content
Cardio Diagnostics (NASDAQ: CDIO) Expands Partnership With Family Medicine Specialists To Bring Specialty Cardiology Tests To Select Walmart Supercenters
A precision cardiovascular medicine company’s innovative AI-driven epigenetic-genetic blood tests will soon be available in one of the nation’s largest retailers.
Partner Content
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Every Story That Matters Around The Web
Peter Schiff Warns Home Prices Could Plunge as Mortgage Lenders Face $2 Trillion In Losses: ‘Already In Worse Shape’ Than During 2008 Crisis
Bernie Sanders Says He Isn't Certain Trump Wouldn't Sign Medicare For All, Urges Democrats to Lower Medicare Eligibility Age to 55: ‘Our Job Is To Produce It’
Marco Rubio Dismisses Exit Rumors, Says Trump Is Paying The 'Price of Leadership' With Tough, Not 'Politically Popular' Calls for America's Future
Jim Cramer Says Nvidia Should Buy Shares on Thursday’s 8% Drop: ‘If the Cheapest Asset is Your Stock, You - Benzinga
